These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Control of severe hyperparathyroidism and regression of a brown tumour after treatment with i.v. alfacalcidol in a uraemic patient. Mourad G; Argilés A; Vela C; Lorho R; Flavier JL; Canaud B; Mion CM Nephrol Dial Transplant; 1995; 10(4):552-4. PubMed ID: 7624003 [No Abstract] [Full Text] [Related]
31. [Dialysis bone disease associated with secondary hyperparathyroidism]. Nakazawa R Nihon Rinsho; 1992 Jan; 50 Suppl():783-8. PubMed ID: 1578767 [No Abstract] [Full Text] [Related]
32. [Treatment of uremic osteopathy. Effects of vitamin D metabolites and vitamin D analogs in chronic uremia and experimental renal insufficiency]. von Herrath D; Kraft D; Schaefer K; Krempien B MMW Munch Med Wochenschr; 1974 Sep; 116(37):1573-8. PubMed ID: 4374654 [No Abstract] [Full Text] [Related]
33. Treatment of bone disease in patients on chronic hemodialysis with dihydrotachysterol. Cordy PE Trans Am Soc Artif Intern Organs; 1976; 22():60-4. PubMed ID: 951878 [TBL] [Abstract][Full Text] [Related]
34. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism. Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956 [TBL] [Abstract][Full Text] [Related]
35. Treatment of bone disease with dihydrotachysterol in patients undergoing long-term hemodialysis. Cordy PE Can Med Assoc J; 1977 Oct; 117(7):766-8. PubMed ID: 907948 [TBL] [Abstract][Full Text] [Related]
36. Thyrocalcitonin: physiological importance and significance in renal failure. Munson PL Am J Med Sci; 1971 Dec; 262(6):310-9. PubMed ID: 4947826 [No Abstract] [Full Text] [Related]
37. Biological activity of endogenous and exogenous calcitonin in patients with osteitis fibrosa and chronic renal failure. Cundy T; Heynen G; Paton S; Ledingham JG; Russell RG; Oliver DO; Kanis JA Proc Eur Dial Transplant Assoc; 1978; 15():524-31. PubMed ID: 740683 [TBL] [Abstract][Full Text] [Related]
38. [Treatment of osteitis fibrosa with 1,25-dihydroxycholecalciferol in patients in treatment with periodic hemodialysis. Effects on the hematochemical and radiological picture]. Docci D; Turci F; Salvi G; Pistocchi E; Pretolani E G Clin Med; 1982; 63(11-12):831-40. PubMed ID: 6897817 [No Abstract] [Full Text] [Related]
39. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
40. Persistence of bone resorptions following treatment of renal osteitis fibrosa. Ellis HA Am J Surg Pathol; 1988 Apr; 12(4):325-6. PubMed ID: 3354757 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]